

## ABOUT INNODIA



## INNODIA HARVEST

The Innovative Medicines Initiative (IMI) initiated by the European Commission has approved an additional section of work on biomarkers and prevention of type 1 diabetes within INNODIA. This additional section builds on the strong base of INNODIA and will be called INNODIA HARVEST. INNODIA has developed a unique European clinical and fundamental research network for the study of type 1 diabetes (T1D). An additional, even more ambitious program is now being proposed in this research network, aimed at 'harvesting' the findings that have already arisen from INNODIA.

Consolidation and innovation are key words.

First, the INNODIA Clinical Network consolidates as a pan-European reference point for conducting studies to prevent or cure T1D. Standardized clinical and bio-research platforms built in INNODIA are upgraded into a powerful network allowing us to conduct clinical trials aimed at preventing and curing T1D. These trials can be both academic and industry sponsored. We are performing smaller, mechanistic, biomarker-rich intervention tests to better understand the development of T1D. Several large studies are underway in the network, notably the MELD-ATG trial (seeking the lowest, safest dose of anti-thymocyte globulin, a Sanofi product, in children with newly-diagnosed T1D), the VER-A-T1D trial (investigating whether verapamil in adults with newly diagnosed T1D can stop disease progression), the Iscalimab study (study investigating children with newly diagnosed T1D or Iscalimab, a Novartis product can safely stop disease progression). In addition, Imcyse, a small Belgian company,

a member of the network is testing its new „Immo-topo“ technology in a small mechanistic study.

The second key word of INNODIA HARVEST is innovation. The network is operating based on the INNODIA Master Protocol, allowing different interventions to be compared. Another innovation is the introduction of new (discovered by the network) biomarkers as well as new clinical (continuous glucose monitoring) and experimental (microbiome analysis) markers, in order to better understand the heterogeneity of T1D and thus lead to faster healing strategies. Furthermore, the basic research of INNODIA's group of researchers is flowing further into INNODIA HARVEST to promote the next generation of target identification and drug development.

Finally, as in INNODIA, the voice of people living with T1D and their families remains at the center of INNODIA HARVEST to drive the implementation of new, patient-centered results, shape our clinical trials and make a meaningful change in the disease perspective.